Company: GEHC
Filing Date: 2025-02-13
Form Type: 10-K
Source: 0001932393-25-000005
Chunk: 115

Company: GE HealthCare Technologies Inc.
Filing Date: 2025-02-13
Form: 10-K
Item: Item 8
Chunk 115
---
29ThereafterTotalUndiscounted lease payments$129 $113 $77 $40 $24 $41 $425 Less: imputed interest40 Total lease liability as of December 31, 2024$385 

80

Supplemental Information Related to Operating LeasesFor the years ended December 31202420232022Operating cash flows used for operating leases$138$130$113Right-of-use assets obtained in exchange for new lease liabilities14715498Weighted-average remaining lease term (in years)4.44.74.4Weighted-average discount rate4.5 %4.4 %3.8 %FINANCE LEASES. The Company leases equipment manufactured or sold by the Company to customers through sales-type leases. Sales-type leases are included in financing receivables and are recognized within All other current assets and All other non-current assets in the Consolidated Statements of Financial Position.Finance lease income was $14 million, $13 million, and $12 million for the years ended December 31, 2024, 2023, and 2022, respectively, and is recognized within Other (income) expense – net in the Consolidated and Combined Statements of Income.Net Investment in Finance LeasesAs ofDecember 31, 2024December 31, 2023Minimum lease payments receivable$242 $236 Less: deferred income(31)(30)Discounted lease receivable211 206 Estimated unguaranteed residual value of leased assets, net of deferred income10 11 Investment in finance leases, net of deferred income$221 $217 Contractual MaturitiesDue In20252026202720282029ThereafterTotalMinimum lease payments receivable$77 $61 $38 $27 $17 $22 $242 We expect actual maturities to differ from contractual maturities, primarily as a result of prepayments.

NOTE 8. ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS

PROPOSED ACQUISITION.On December 1, 2024, we announced an agreement to acquire the remaining stake in the Nihon Medi-Physics Co., Ltd (“NMP”) equity method investment to assume full ownership. NMP is a leading pharmaceutical manufacturer in Japan, focused on radiopharmaceuticals, which are used to enable clinical images across neurology, cardiology, and oncology procedures,